Lower-risk Myelodysplastic Syndromes: Data Updates and Evolving Treatment Paradigms in the Frontline Setting

Two expert oncologists review the standard-of-care and unmet needs in the treatment of lower-risk Myelodysplastic Syndromes [MDS]. They discuss emerging data on novel therapies and consider their impact on the treatment landscape for patients with lower-risk MDS.